Literature DB >> 23912646

Cytokine expression before and after aspirin desensitization therapy in aspirin-exacerbated respiratory disease.

Ayse Aktas1, Emel Kurt, Zafer Gulbas.   

Abstract

Aspirin exacerbated respiratory disease (AERD) is induced by acetylsalicylic acid (ASA) and/or nonsteroidal antiinflammatory drugs (NSAIDs). Effects of desensitization on many mediators have been examined previously, but few studies addressed the influence of desensitization on T lymphocytes and T lymphocyte-derived cytokines. This study was performed to examine peripheral blood lymphocyte (PBL) cytokine expression in aspirin-sensitive patients who have asthma before and after aspirin desensitization. In this study, the release of interleukin-2 (IL-2), interleukin-4 (IL-4), and interferon-gamma (IFN-γ) by CD4+ T lymphocytes prior to aspirin desensitization were also measured at intracellular levels, and expression of these cytokines after 1 month aspirin desensitization was evaluated. Twelve patients with AERD were included in the study. Two different control groups were formed, one consisted of 15 healthy people and second 12 aspirin tolerant asthmatic (ATA) patients using aspirin. A blood sample was collected prior to desensitization, and the tests were repeated by taking a second blood sample 1 month after the 4-day desensitization treatment. The proportion of lymphocytes secreting IFN-γ in the study group was 15.61 ± 4.40 % before desensitization and 15.08 ± 5.89 % after desensitization. The rate of IFN-γ secreting CD4+ T lymphocytes was 20.51 ± 4.41 % in the normal control group and 16.07 ± 5.7 % in the ATA group (p = 0.021). The ratio of CD4+ T lymphocyte secreting IFN-γ was reduced in patients with AERD before desensitization compared to normal control group (p = 0.040). The levels of IL-2, IL-4, and the subsets of lymphocyte were not different before and after desensitization compared to control groups.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912646     DOI: 10.1007/s10753-013-9699-7

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  32 in total

1.  Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma.

Authors:  C H Marquette; F Saulnier; O Leroy; B Wallaert; C Chopin; J M Demarcq; A Durocher; A B Tonnel
Journal:  Am Rev Respir Dis       Date:  1992-07

2.  Cyclooxygenase metabolism of endogenous arachidonic acid by cultured human tracheal epithelial cells.

Authors:  L Churchill; F H Chilton; J H Resau; R Bascom; W C Hubbard; D Proud
Journal:  Am Rev Respir Dis       Date:  1989-08

3.  Cytokine expression in peripheral blood lymphocytes before and after aspirin desensitization in aspirin-exacerbated respiratory disease.

Authors:  Goutam P Shome; James Tarbox; Michael Shearer; Ronald Kennedy
Journal:  Allergy Asthma Proc       Date:  2007 Nov-Dec       Impact factor: 2.587

4.  Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs.

Authors:  D D Stevenson
Journal:  J Allergy Clin Immunol       Date:  1984-10       Impact factor: 10.793

Review 5.  Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management.

Authors:  Andrew Szczeklik; Donald D Stevenson
Journal:  J Allergy Clin Immunol       Date:  2003-05       Impact factor: 10.793

6.  Arachidonic acid metabolism in monocytes of aspirin-sensitive asthmatic patients before and after oral aspirin challenge.

Authors:  U R Juergens; S C Christiansen; D D Stevenson; B L Zuraw
Journal:  J Allergy Clin Immunol       Date:  1992-10       Impact factor: 10.793

7.  Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects.

Authors:  P E Christie; P Tagari; A W Ford-Hutchinson; S Charlesson; P Chee; J P Arm; T H Lee
Journal:  Am Rev Respir Dis       Date:  1991-05

8.  The effect of aspirin on mononuclear cells in aspirin-sensitive asthmatics and control subjects.

Authors:  M L Taylor; G A Stewart; P J Thompson
Journal:  Int Arch Allergy Immunol       Date:  1993       Impact factor: 2.749

9.  Inhibition of monocyte leukotriene B4 production after aspirin desensitization.

Authors:  U R Juergens; S C Christiansen; D D Stevenson; B L Zuraw
Journal:  J Allergy Clin Immunol       Date:  1995-08       Impact factor: 10.793

10.  Decreased frequency of interferon-gamma- and interleukin-2-producing cells in patients with atopic diseases measured at the single cell level.

Authors:  T Jung; G Lack; U Schauer; W Uberück; H Renz; E W Gelfand; C H Rieger
Journal:  J Allergy Clin Immunol       Date:  1995-10       Impact factor: 10.793

View more
  6 in total

1.  Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?

Authors:  Ludger Klimek; Ralph Dollner; Oliver Pfaar; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.806

Review 2.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

3.  The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data.

Authors:  Marion San Nicoló; Catalina Högerle; Donata Gellrich; Katharina Eder; Elisabeth Pfrogner; Moritz Gröger
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-10-26       Impact factor: 2.503

4.  Interleukin-10 is increased in successful drug desensitization regardless of the hypersensitivity reaction type.

Authors:  Aslı Gelincik; Semra Demir; Fatma Şen; Uğur Hamza Bozbey; Müge Olgaç; Derya Ünal; Bahauddin Çolakoğlu; Esin Çetin Aktaş; Günnur Deniz; Suna Büyüköztürk
Journal:  Asia Pac Allergy       Date:  2019-01-28

5.  Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease.

Authors:  Negar Mortazavi; Hossein Esmaeilzadeh; Mohammad Abbasinazari; Delara Babaie; Soheila Alyasin; Hesamodin Nabavizadeh; Elmira Esmailzadeh
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

Review 6.  NSAID-induced reactions: classification, prevalence, impact, and management strategies.

Authors:  Natalia Blanca-Lopez; Victor Soriano; Elena Garcia-Martin; Gabriela Canto; Miguel Blanca
Journal:  J Asthma Allergy       Date:  2019-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.